Evaluating a synergistic nutritional strategy in women with polycystic ovary syndrome: a multicentric retrospective analysis
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20253506Keywords:
Antioxidants, Infertility, Inositols, PCOS, PregnancyAbstract
Background: The objective of this study was to review clinical outcomes in women with polycystic ovary syndrome (PCOS) following 3-6 months of treatment with the marketed formulations containing insulin sensitizers, minerals, herbal extracts, amino acids, antioxidants, and vitamins.
Methods: An observational study was conducted to retrospectively review clinical records of women diagnosed with PCOS (age 15-42 years; n=211) at 14 fertility clinics in India between April 2024 and February 2025. From the day of PCOS diagnosis, patients received marketed formulations containing (1) insulin-sensitizing agents, antioxidants, and vitamins and (2) fertility blend containing herbal extracts, amino acids and minerals administered as two tablets daily for 3 to 6 months. The primary outcomes assessed were improvements in PCOS symptoms such as (menstrual cyclicity, acne, and hirsutism), body mass index (BMI), waist-to-hip ratio, ovarian cyst count, hormonal profile, and clinical pregnancy rates.
Results: Combination therapy significantly improved menstrual cyclicity in both obese (40% at 3 months; 80.56% at six months) and lean (42.30% at three months; 69.23% at 6 months) PCOS women. Significant reductions in acne, hirsutism, and ovarian cysts were observed across both the groups. Additionally, metabolic parameters and hormonal profiles improved significantly. The clinical pregnancy rate increased to 36.78% at three months and 65.16% at six months in obese women, while lean women showed rates of 38.46% and 53.84% respectively.
Conclusions: The combination of inositols, antioxidants, herbal extracts, amino acids, minerals, and vitamins offer a promising and clinically relevant treatment option for PCOS management, demonstrating significant benefits in metabolic, hormonal, and reproductive health.
Metrics
References
Hajam YA, Rather HA, Kumar NR, Basheer M, Reshi MS. A review on critical appraisal and pathogenesis of polycystic ovarian syndrome. Endocr Metab Sci. 2024;14:100162. DOI: https://doi.org/10.1016/j.endmts.2024.100162
Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020;35:100937. DOI: https://doi.org/10.1016/j.molmet.2020.01.001
Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC, et al. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575-92. DOI: https://doi.org/10.1093/humupd/dmv029
Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A, et al. Epidemiology, pathogenesis, genetics and management of polycystic ovary syndrome in India. Indian J Med Res. 2019;150(4):333-44. DOI: https://doi.org/10.4103/ijmr.IJMR_1937_17
Barber TM. Why are women with polycystic ovary syndrome obese? Br Med Bull. 2022;143(1):4-15. DOI: https://doi.org/10.1093/bmb/ldac007
Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxidat Med Cell Long. 2016;2016(1):8589318. DOI: https://doi.org/10.1155/2016/8589318
Butler AE, Dargham SR, Abouseif A, El Shewehy A, Atkin SL. Vitamin D deficiency effects on cardiovascular parameters in women with polycystic ovary syndrome: a retrospective, cross-sectional study. J Steroid Biochem Mol Biol. 2021;211:105892. DOI: https://doi.org/10.1016/j.jsbmb.2021.105892
Houston EJ, Templeman NM. Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS. J Endocrinol. 2025;265(2):e240269. DOI: https://doi.org/10.1530/JOE-24-0269
Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019;3(8):1545-73. DOI: https://doi.org/10.1210/js.2019-00078
Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, et al. Inositols: from established knowledge to novel approaches. Int J Mol Sci. 2021;22(19):10575. DOI: https://doi.org/10.3390/ijms221910575
Schachter M. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod. 2003;18(4):721-7. DOI: https://doi.org/10.1093/humrep/deg190
Advani K, Batra M, Tajpuriya S, Gupta R, Saraswat A, Nagar HD, et al. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study. J Obstet Gynaecol. 2020;40(1):96-101. DOI: https://doi.org/10.1080/01443615.2019.1604644
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19 (1):41-7. DOI: https://doi.org/10.1093/humrep/deh098
Fang YQ, Ding H, Li T, Zhao XJ, Luo D, Liu Y, et al. N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome. J Ovar Res. 2024;7(1):205. DOI: https://doi.org/10.1186/s13048-024-01528-8
Calcaterra V, Verduci E, Cena H, Magenes VC, Todisco CF, Tenuta E, et al. Polycystic ovary syndrome in insulin-resistant adolescents with obesity: the role of nutrition therapy and food supplements as a strategy to protect fertility. Nutrients. 2021;13(6):1848. DOI: https://doi.org/10.3390/nu13061848
Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol. 2014;30(6):438-43. DOI: https://doi.org/10.3109/09513590.2014.897321
Yasmin A, Roychoudhury S, Paul Choudhury A, Ahmed ABF, Dutta S, Mottola F, et al. Polycystic ovary syndrome: an updated overview foregrounding impacts of ethnicities and geographic variations. Life. 2022;12(12):1974. DOI: https://doi.org/10.3390/life12121974
Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12(4):1454. DOI: https://doi.org/10.3390/jcm12041454
Tippairote T, Bjørklund G, Gasmi A, Semenova Y, Peana M, Chirumbolo S, et al. Combined supplementation of coenzyme Q10 and other nutrients in specific medical conditions. Nutrients. 2022;14(20):4383. DOI: https://doi.org/10.3390/nu14204383
Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril. 2012;97(1):18-22. DOI: https://doi.org/10.1016/j.fertnstert.2011.11.036
Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042. DOI: https://doi.org/10.1177/1179558119874042
Sam S. Obesity and polycystic ovary syndrome. Obes Manage. 2007;3(2):69-73. DOI: https://doi.org/10.1089/obe.2007.0019
Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera MA. Combined therapy with myo-inositol and d-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol. 2016:1-5. DOI: https://doi.org/10.1155/2016/3204083
Ashoush S, Abou‐Gamrah A, Bayoumy H, Othman N. Chromium picolinate reduces insulin resistance in polycystic ovary syndrome: randomized controlled trial. J Obstet Gynaecol Res. 2016;42(3):279-85. DOI: https://doi.org/10.1111/jog.12907
Chaudhuri A. Polycystic ovary syndrome: Causes, symptoms, pathophysiology, and remedies. Obes Med. 2023;39:100480. DOI: https://doi.org/10.1016/j.obmed.2023.100480
Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687-708. DOI: https://doi.org/10.1093/humupd/dmw025
Zhang SW, Zhou J, Gober HJ, Leung WT, Wang L. Effect and mechanism of berberine against polycystic ovary syndrome. Biomed Pharmacother. 2021;138:111468. DOI: https://doi.org/10.1016/j.biopha.2021.111468
Laganà AS, Garzon S, Unfer V. New clinical targets of D-chiro-inositol: rationale and potential applications. Exp Opin Drug Metab Toxicol. 2020;16(8):703-10. DOI: https://doi.org/10.1080/17425255.2020.1785429
Rondanelli M, Riva A, Petrangolini G, Allegrini P, Giacosa A, Fazia T, et al. Berberine phospholipid is an effective insulin sensitizer and improves metabolic and hormonal disorders in women with polycystic ovary syndrome: a one-group pretest-post-test explanatory study. Nutrients. 2021;13(10):3665. DOI: https://doi.org/10.3390/nu13103665
Maleki V, Taheri E, Varshosaz P, Tabrizi FPF, Moludi J, Jafari-Vayghan H, et al. A comprehensive insight into effects of green tea extract in polycystic ovary syndrome: a systematic review. Reprod Biol Endocrinol. 2021;19(1):147. DOI: https://doi.org/10.1186/s12958-021-00831-z
Mancini A, Bruno C, Vergani E, d’Abate C, Giacchi E, Silvestrini A, et al. Oxidative stress and low-grade inflammation in polycystic ovary syndrome: controversies and new insights. Int J Mol Sci. 2021;22(4):1667. DOI: https://doi.org/10.3390/ijms22041667
Aboeldalyl S, James C, Seyam E, Ibrahim EM, Shawki HE, Amer S. The role of chronic inflammation in polycystic ovarian syndrome- a systematic review and meta-analysis. Int J Mol Sci. 2021;22(5):2734. DOI: https://doi.org/10.3390/ijms22052734
Vale-Fernandes E, Moreira MV, Rodrigues B, Pereira SS, Leal C, Barreiro M, et al. Anti-Müllerian hormone a surrogate of follicular fluid oxidative stress in polycystic ovary syndrome? Front Cell Dev Biol. 2024;12:1408879. DOI: https://doi.org/10.3389/fcell.2024.1408879
Fulghesu AM, Ciampelli M, Muzj G, Belosi C, Selvaggi L, Ayala GF, et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril. 2002;77(6):1128-35. DOI: https://doi.org/10.1016/S0015-0282(02)03133-3
Fernando S, Rombauts L. Melatonin: shedding light on infertility?- a review of the recent literature. J Ovar Res. 2014;7(1):98. DOI: https://doi.org/10.1186/PREACCEPT-1516771013137283
Shafie A, Aleyasin A, Saffari M, Saedi M, Rostami S, Rezayi S, et al. Astaxanthin improves assisted reproductive technology outcomes in poor ovarian responders through alleviating oxidative stress, inflammation, and apoptosis: a randomized clinical trial. J Ovar Res. 2024;17(1):212. DOI: https://doi.org/10.1186/s13048-024-01537-7
Puglia LT, Lowry J, Tamagno G. Vitex agnus castus effects on hyperprolactinaemia. Front Endocrinol. 2023;14:1269781. DOI: https://doi.org/10.3389/fendo.2023.1269781
Montville CP, Khabbaz M, Aubuchon M, Williams DB, Thomas MA. Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation induction. Fertil Steril. 2010;94(2):678-83. DOI: https://doi.org/10.1016/j.fertnstert.2009.03.088
Dennett CC, Simon J. The role of polycystic ovary syndrome in reproductive and metabolic health: overview and approaches for treatment. Diabetes Spectr. 2015;28(2):116-20. DOI: https://doi.org/10.2337/diaspect.28.2.116
Chen Y, Yang J, Zhang L. The impact of follicular fluid oxidative stress levels on the outcomes of assisted reproductive therapy. Antioxidants. 2023;12(12):2117. DOI: https://doi.org/10.3390/antiox12122117
Downloads
Published
How to Cite
Issue
Section
